Hajime Hosoi, Mitsuru Miyachi, Satoshi Teramukai, Satomi Sakabayashi, Kunihiko Tsuchiya, Yasumichi Kuwahara, Rie Onodera, Kotone Matsuyama, Isao Yokota, Hiroshi Hojo, et al. Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma. International journal of clinical oncology. 2024
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, et al. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer discovery. 2024
Yasumichi Kuwahara, Tomoko Iehara, Akifumi Matsumoto, Tsukasa Okuda. Recent insights into the SWI/SNF complex and the molecular mechanism of hSNF5 deficiency in rhabdoid tumors. Cancer medicine. 2023
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, et al. RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells. 2022. 45. 12. 886-895
Haruka Shinohara, Rie Sawado, Makoto Nakagawa, Ayuna Hattori, Kazutsune Yamagata, Kimiharu Tauchi, Jumpei Ito, Yasumichi Kuwahara, Tsukasa Okuda, Chitose Ogawa, et al. Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors. Molecular therapy oncolytics. 2022. 27. 14-25